Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Idorsia and SPV investors partner to commercialize TRYVIO/JERAYGO with a targeted launch for specialists.
Oct 29, 2026
Contract Type
partnership
The United States
Description
Idorsia has announced a commercialization partnership with noteholders in Idorsia Investments SARL to unlock the potential of TRYVIO/JERAYGO. The partnership combines dedicated launch capital of CHF 120 million with participation in future revenues, aiming to enhance commercialization efforts in the cardiovascular medication space.
Company Information
Company
Idorsia
Location
The United States, Washington, United States
About
In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success. Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options.